-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 NLyq/3KBvugdwCl1B9xgHMSJZr1Z/rGkKHB4AjQ2WHjPHSgneoT4TvdwFledxGZr
 feNayfd/eT1V0rLa6PJvEw==

<SEC-DOCUMENT>0000927946-03-000223.txt : 20031106
<SEC-HEADER>0000927946-03-000223.hdr.sgml : 20031106
<ACCEPTANCE-DATETIME>20031106162511
ACCESSION NUMBER:		0000927946-03-000223
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20031031
ITEM INFORMATION:		Other events
ITEM INFORMATION:		Financial statements and exhibits
FILED AS OF DATE:		20031106

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOANALYTICAL SYSTEMS INC
		CENTRAL INDEX KEY:			0000720154
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				351345024
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23357
		FILM NUMBER:		03982625

	BUSINESS ADDRESS:	
		STREET 1:		2701 KENT AVE
		CITY:			WEST LAFAYETT
		STATE:			IN
		ZIP:			47906-1382
		BUSINESS PHONE:		3174634527

	MAIL ADDRESS:	
		STREET 1:		2701 KENT AVENUE
		CITY:			WEST LAFAYETTE
		STATE:			IN
		ZIP:			47906-1382
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>bas8k.htm
<DESCRIPTION>BAS 8K DATED OCTOBER 31, 2003
<TEXT>









<HTML>
<HEAD>
<Title>Bioanalytical Systems, Inc. - Form 8K (dated 10/31/2003</title></head>
<BODY>

<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=3>
<b>UNITED STATES</b><br>
<b>SECURITIES AND EXCHANGE COMMISSION</b></FONT><br>
<FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<b>Washington, D.C. 20549</b></font></P>
<br>

<hr width=30% noshade>

<p align=center><FONT FACE="Times New Roman, Times, Serif" size=4>
<b>FORM 8-K</b><BR><br>
<B>CURRENT REPORT</B><BR><br>
<b><small>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</small></b>
</font></p>
<hr width=30% noshade>

<p><FONT FACE="Times New Roman, Times, Serif" SIZE=3>
Date of Report (Date of earliest event reported):&nbsp;&nbsp;<b>October 31, 2003</b>
</font></p>
<br>
<br>
<br>
<p align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=4>
<b><u>BIOANALYTICAL SYSTEMS, INC.</u></b><br>
<small><small><small>(Exact name of registrant as specified in its charter)</small></small></small>
</font></P>

<table width=95% border=0>
<tr valign=bottom><td align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3>
<u>Indiana</u></font></td>
<TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3><u>
0-23357</u></font></td>
<TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3><u>
35-1345024</u></font></td></TR>

<TR VALIGN=TOP>
<TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(State or other jurisdiction of<br>incorporation or organization)</font></TD>
<td align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(Commission File Number)</font></td>
<td align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(IRS Employer Identification No.)</font></td></TR>
<tr><TD><br></TD></tr>

<TR VALIGN=bottom><TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3>
2701 Kent Avenue<br>
<u>West Lafayette, Indiana</u></font></TD>
<TD></TD> <td align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3><br>
<u>47906-1382</u></font></td></TR>
<TR VALIGN=top><TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(Address of principal executive offices)</font></TD><TD>
</TD><td align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(Zip Code)</font></td></TR>
<tr><TD></TD></tr>
<TR VALIGN=top><TD> </TD><TD align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3><u>
(765) 463-4527</u></font></TD></TR>
<TR VALIGN=top><TD> </TD><TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(Registrant's telephone number, including area code)</font></TD></TR>
</TABLE>



<PAGE>



<!-- MARKER FORMAT-SHEET="Head Left" FSL="Workstation" -->
<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Item 5.</FONT></P>

<!-- MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Default" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On October 30, 2003,
Bioanalytical Systems, Inc. (the &#147;Company&#148;) issued the press release
filed herewith as Exhibit 99.1, and incorporated herein by reference,
announcing the resignation of its Chief Financial Officer, Douglas P.
Wieten.</FONT></P>

<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
Item 7.&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.</font></P>

<!-- MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Default" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following exhibits are filed
as a part of this report:</FONT></P>

<!-- MARKER FORMAT-SHEET="Head Sub 2 Left" FSL="Default" -->
<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Exhibits</FONT></P>


<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Press release, dated October 30, 2003, announcing the resignation of its Chief
Financial Officer, Douglas P. Wieten.</font></P>



<PAGE>


<!-- MARKER FORMAT-SHEET="Head Major Center Bold" FSL="Workstation" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
SIGNATURES </FONT></H1>
<BR>

<!-- MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Default" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned hereunto duly
authorized.</FONT></P>


<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR>
<TD width=60%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Date:&nbsp;&nbsp;November 6, 2003</FONT></TD>
<TD width=40%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<U>BIOANALYTICAL SYSTEMS, INC.</U><br>
(Registrant)<br>
<br>
<br>
<br>
By:&nbsp;&nbsp;/s/ Michael P. Silvon<hr>
Michael P. Silvon<br>
Vice President, Planning and Development<BR>
Interim Chief Financial Officer and Treasurer<br></FONT>
</TD>
</TR>
</TABLE>


<PAGE>


<!-- MARKER FORMAT-SHEET="Head Major Center Bold 1" FSL="Default" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<U>Exhibit Index</U> </FONT></H1>
<BR>


<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=20%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Item Number<BR>
assigned in<BR>
<U>Regulation S-K</U></FONT></TD>

<TD valign=bottom WIDTH=20%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<u>Exhibit</U></FONT></TD>

<TD valign=bottom WIDTH=60%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<u>Description of Exhibits</U></FONT></TD>
</TR>
</TABLE>
<BR>

<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=20%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99</FONT></TD>

<TD valign=bottom WIDTH=20%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
(99.1)</FONT></TD>

<TD valign=bottom WIDTH=60%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Press release dated October 31, 2003</FONT></TD>
</TR>
</TABLE>

</BODY>
</HTML>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>exhibit991.htm
<DESCRIPTION>PRESS RELEASE DATED 10/31/2003
<TEXT>



<HTML>
<HEAD>
<TITLE>Exhibit 99.1 - Press Release dated October 31, 2003</TITLE>
</HEAD>
<BODY>


<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" size=2>
Exhibit 99.1</font></P>
<BR>


<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<p ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=3>
<B>Douglas P. Wieten Steps Down as Bioanalytical Systems, Inc. CFO</B><BR>
<small>Friday October 31, 10:55 am ET</small></FONT></p>
<BR>

<!-- MARKER FORMAT-SHEET="Head Left" FSL="Workstation" -->
<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
WEST LAFAYETTE, Ind. &#151; (BUSINESS WIRE) &#151; Oct. 31, 2003 &#151;
Bioanalytical Systems, Inc. (Nasdaq:<U>BASI</U> &#151; <U>News</U>) today
announced that Douglas P. Wieten is leaving his position as Chief Financial
Officer and Treasurer of BASi to pursue other opportunities effective October
31, 2003. The Company has named Michael P. Silvon, Vice President, Planning and
Development as interim CFO and will promptly begin a search for a permanent
CFO.</FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Headquartered in West Lafayette, Indiana BASi provides contract development
services and research equipment to pharmaceutical, medical device and
biotechnology companies. These companies use BASi&#146;s services and equipment
to improve the speed and efficiency of preclinical, clinical and analytical
development of their products. Scientists engaged in drug metabolism studies,
pharmacokinetics and basic neuroscience research at pharmaceutical research
organizations are BASi&#146;s principal clients. BASi&#146;s services group
provides screening and pharmacological testing, preclinical/safety testing,
formulation development, regulatory compliance and quality control
testing.</FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Default" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
This release contains forward-looking statements that are subject to risks and
uncertainties including, but not limited to, risks and uncertainties related to
the development of products and services, changes in technology, industry
standards and regulatory standards, and various market and operating risks
detailed in the company&#146;s filings with the Securities and Exchange
Commission.</FONT></P>
<BR>
<BR>

<!-- MARKER FORMAT-SHEET="Head Left" FSL="Default" -->
<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<hr align=left width=20%>
<I>Contact:</I><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<small>Bioanalytical Systems, Inc.</small><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<small>Michael P. Silvon, 765-497-5831</small><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<small><U>silvon@bioanalytical.com</U></small></FONT></P>

</BODY>
</HTML>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
